We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

79 hedge funds and large institutions have $372M invested in Foghorn Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more call options, than puts

Call options by funds: $92K | Put options by funds: $22K

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

64% more capital invested

Capital invested by funds: $227M → $372M (+$146M)

53% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 19

10% more funds holding

Funds holding: 72 → 79 (+7)

1% more ownership

Funds ownership: 71.29% → 72.29% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
79
Holders Change
+7
Holders Change %
+9.72%
% of All Funds
1.13%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
29
Reduced
19
Closed
6
Calls
$92K
Puts
$22K
Net Calls
+$70K
Net Calls Change
+$46K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$4.87M
2
DM
Deerfield Management
New York
+$3.69M
3
BlackRock
BlackRock
New York
+$1.92M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.06M
5
TI
Trexquant Investment
Connecticut
+$439K

Top Sellers

1
AG
Artal Group
Luxembourg
-$4.14M
2
DCM
Driehaus Capital Management
Illinois
-$3.27M
3
PA
Perceptive Advisors
New York
-$3.13M
4
Focus Partners Wealth
Focus Partners Wealth
Massachusetts
-$1.29M
5
PAM
Panagora Asset Management
Massachusetts
-$429K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$118M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$59M -$357K -49,307 -0.8%
BI
3
BVF Inc
California
$49.4M – – –
DM
4
Deerfield Management
New York
$28.2M +$3.69M +509,386 +20%
RJA
5
Raymond James & Associates
Florida
$21.4M -$298K -41,104 -2%
BlackRock
6
BlackRock
New York
$16.9M +$1.92M +265,233 +17%
Vanguard Group
7
Vanguard Group
Pennsylvania
$16.1M +$4.87M +672,494 +63%
EC
8
Euclidean Capital
New York
$14.7M – – –
SL
9
Siren LLC
Connecticut
$6.71M +$5.22M +720,720 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$6.31M +$1.06M +146,276 +28%
State Street
11
State Street
Massachusetts
$4.71M +$171K +23,630 +5%
AI
12
Alphabet Inc
California
$4.66M – – –
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$3.72M -$50.2K -6,939 -2%
BC
14
Birchview Capital
Vermont
$2.99M – – –
Northern Trust
15
Northern Trust
Illinois
$2.33M +$433K +59,847 +31%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$1.2M -$398K -54,973 -30%
SCM
17
Sio Capital Management
New York
$1.13M – – –
Morgan Stanley
18
Morgan Stanley
New York
$1.01M +$312K +43,103 +66%
RWM
19
Rockwood Wealth Management
Pennsylvania
$999K – – –
Citadel Advisors
20
Citadel Advisors
Florida
$756K +$118K +16,354 +25%
Charles Schwab
21
Charles Schwab
California
$703K +$50.7K +7,000 +10%
Wellington Management Group
22
Wellington Management Group
Massachusetts
$672K +$206K +28,427 +65%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$649K +$318K +43,958 +171%
TI
24
Trexquant Investment
Connecticut
$564K +$439K +60,604 New
N
25
Nuveen
North Carolina
$563K -$53.8K -7,428 -11%
1
2 3 4

FHTX Hedge Fund Activity: Q3 2024 in Review

79 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2024, worth a combined $372M — up 64% from $227M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new FHTX positions and 6 closed out — a net gain of 7 holders — while 29 added to existing stakes and 19 trimmed.

The largest buyer was Vanguard Group, adding an estimated $4.87M. The largest seller was Artal Group, exiting entirely with an estimated $4.14M sold.

  • 79 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2024, up from 72 in Q2 2024.
  • Funds reported $372M of Foghorn Therapeutics stock for Q3 2024, up 64% quarter-over-quarter.
  • 13 funds opened new Foghorn Therapeutics positions in Q3 2024 and 6 closed out, a net change of +7 holders.
  • The largest Foghorn Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $4.87M added.
  • The largest Foghorn Therapeutics seller in Q3 2024 was Artal Group, an estimated $4.14M sold.

Based on aggregated 13F filings for Q3 2024.